Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD

The aim of this study was to assess the impact of chronic kidney disease (CKD) on the safety and efficacy of ticagrelor monotherapy among patients undergoing percutaneous coronary intervention (PCI). In this prespecified subanalysis of the TWILIGHT trial, we evaluated the treatment effects of ticagr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European heart journal 2021-12, Vol.42 (45), p.4683-4693
Hauptverfasser: Stefanini, Giulio G, Briguori, Carlo, Cao, Davide, Baber, Usman, Sartori, Samantha, Zhang, Zhongjie, Dangas, George, Angiolillo, Dominick J, Mehta, Shamir, Cohen, David J, Collier, Timothy, Dudek, Dariusz, Escaned, Javier, Gibson, C Michael, Gil, Robert, Huber, Kurt, Kaul, Upendra, Kornowski, Ran, Krucoff, Mitchell W, Kunadian, Vijay, Moliterno, David J, Ohman, E Magnus, Oldroyd, Keith G, Sardella, Gennaro, Sharma, Samin K, Shlofmitz, Richard, Weisz, Giora, Witzenbichler, Bernhard, Pocock, Stuart, Mehran, Roxana
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The aim of this study was to assess the impact of chronic kidney disease (CKD) on the safety and efficacy of ticagrelor monotherapy among patients undergoing percutaneous coronary intervention (PCI). In this prespecified subanalysis of the TWILIGHT trial, we evaluated the treatment effects of ticagrelor with or without aspirin according to renal function. The trial enrolled patients undergoing drug-eluting stent implantation who fulfilled at least one clinical and one angiographic high-risk criterion. Chronic kidney disease, defined as an estimated glomerular filtration rate (eGFR)
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/ehab533